

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 693 278 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**24.01.1996 Bulletin 1996/04**

(51) Int. Cl.<sup>6</sup>: **A61K 7/06, A61K 7/48**

(21) Application number: **95110908.1**

(22) Date of filing: **12.07.1995**

(84) Designated Contracting States:

**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE**

(30) Priority: **19.07.1994 IT MI941497**

(71) Applicant: **INDENA S.p.A.**

**I-20141 Milano (IT)**

(72) Inventors:

- **Bombardelli, Ezio**  
**I-20141 Milano (IT)**
- **Cristoni, Aldo**  
**I-20141 Milano (IT)**
- **Morazzoni, Paolo**  
**I-20141 Milano (IT)**

(74) Representative: **Bianchetti, Giuseppe**

**I-20122 Milan (IT)**

(54) **Combinations of vasoactive substances with fatty acids to prevent hair loss**

(57) The present invention relates to novel formulations useful in the preventive and curative treatment of hair loss and of seborrhea, containing coumarins such as khellin, visnadin, esculoside or alkaloids such as rau-basine, vincamine and derivatives thereof, combined with unsaturated and saturated fatty acids.

**EP 0 693 278 A2**

## Description

The present invention relates to novel formulations useful in the preventive and curative treatment of hair loss, containing combinations of substances activating the microcirculation of "galea capitis" and products having antiseborrhoic and antiandrogen actions. It has surprisingly been found that formulations containing coumarins such as khellin, visnadin, esculoside, or alkaloids such as raubasine, vincamine and derivatives thereof, combined with unsaturated fatty acids such as ximenynic acid, the ethyl ester or other esters thereof, as well as acids such as lauric, myristic or isomyristic acids, are synergistically active in stimulating hair regrowth or in preventing its loss.

The vasokinetic activity of some of these substances, such as visnadin and khellin, had already been described in Patent application IT-21786A/89, which evidenced the effect thereof on the increase in the volume and in the blood flow rate at the level of the capillary network, and the use of these substances in peripheral vasculopathies and in primitive and secondary alopecias had been provided. Similarly, ximenynic acid free or in the form of triglyceride and generally of esters, was found to increase the blood flow with mechanisms different from those of visnadin and khellin (Patent IT-1223290).

Ximenynic acid and the esters thereof, when applied topically for a long time, exert a double effect at the cutaneous level: a microvasculokinetic one and antiseborrhoic one. Such two actions combined in the same molecule are particularly useful for keeping the skin effectively vascularized and at the same time dry thanks to a decreased sebum secretion. C<sub>12</sub> and C<sub>14</sub> acids, such as lauric, myristic and isomyristic acids, turned out to be strong inhibitors of dihydrotestosterone receptor binding, therefore, when suitably carried through the epicutaneous layer, they can exert a remarkable antiandrogen action thus contributing to a sebaceous regulation.

The combination of substances with vasokinetic activity (coumarins or alkaloids) with unsaturated fatty acids or the esters thereof as antiseborrhoic agents and with C<sub>12</sub> and C<sub>14</sub> acids with antiandrogen activity is one of the objects of the invention, and is proved to be particularly useful for stimulating the hair follicle and keeping the skin nourished thanks to a higher supply of blood and therefore of trophic substances; as result, after some days of treatment, a marked change in the skin occurs, with an increased number of perfused capillaries and absence of dandruff; hair follicles are normal and patent, and the sebum production is normal.

The above mentioned products, when combined together, are suitable for the administration in the form of hydroalcoholic lotions (which are those preferred for treatments of the scalp) or in the form of gels.

The preferred combinations for said treatments contain a combination of visnadin or khellin, in concentrations ranging from 0.2% to 3%; ximenynic acid or esters thereof, in concentrations ranging from 0.2% to 10% (preferably 1.5%); and lauric acid in concentrations ranging from 0.1% to 1% (preferably 0.5%). Visnadin and khellin can advantageously be replaced by esculoside or by its aglucon esculetin, in concentrations varying from 0.3% to 4% (preferably 2%).

Esculoside, in combination with ximenynic acid and the esters thereof and lauric, myristic and isomyristic acids, is particularly suitable for the treatment of early hair loss and for the stimulation of hair growth. The treatment with these substances can vary from a few days to 6 months.

## PHARMACOLOGICAL EXPERIMENTATION

30 Subjects with primary or secondary alopecia were subdivided into 3 groups of 10 individuals each and treated for 90 days respectively with:

**Group 1:** a formulation containing 1% esculoside;

**Group 2:** a formulation containing 0.5% ximenynic acid and 0.2% lauric acid;

**Group 3:** a formulation containing 1% esculoside, 0.5% ximenynic acid and 0.2% lauric acid.

The vasokinetic effects and those on trichogram were evaluated both at the beginning and the end of the treatment.

Trichogram (basal and after 90 days) consists in withdrawing a suitable number (about 50) of hair by means of rubberized tweezers, both at the frontal-superior and latero-nuchal areas (Bosse K., Hautzart, 18, 35, 1967; Bosse K., Hautzart 18, 218, 1967).

Microscope observation of hair roots allows to evaluate the percentage of hair in anagen (growth), catagen (mature) or telogen (latency) phases. A telogen percentage higher than 10-15% (which is considered normal) gives a clinical evidence of a pathological condition of hair loss (Mortimer C.H., Rushton H., James K.C., Clin. Exp. Dermatol., 9, 342, 1984).

The vasokinetic effects were tested using the laser-Doppler flowmetry (Nilsson G.E., Tenland T., Oberg P.A., IEEE Transaction Biochem. Eng., 27, 12, 1980) using the PeriFlux<sup>R</sup> PF3 flowmeter. This technique made it possible to measure the blood flow of the scalp of the subjects under test, under basal conditions and after administration of the test formulations, 15 minutes after the first administration (acute effect) and 8 hours after the administration, at the 30th, 60th and 90th day of treatment.

The results reported in Table 1 show the efficacy of esculoside as a vasokinetic agent.

The combination of said compound with ximenynic and lauric acids exerts a significant action on the hair follicle, so as to synergistically stimulate the regrowth or decrease the hair loss (13% telogen after a 90 day treatment), compared with the administration of the single components (Table 2).

**Table 1**  
Effects on the average capillary blood flow induced by the topical administration of esculoside (group 1), ximenynic acid + lauric acid (group 2) and esculoside + ximenynic acid + lauric acid (group 3).

Treatment	Capillary flow (AU $\pm$ s.e.)				
	Basal	15 minutes	30 days	60 days	90 days
Group 1	9.2 $\pm$ 1.0	23.1 $\pm$ 3.0*	11.7 $\pm$ 2.4	16.8 $\pm$ 1.2*	16.7 $\pm$ 1.1*
Group 2	9.4 $\pm$ 1.2	10.0 $\pm$ 1.3	10.7 $\pm$ 1.5	11.0 $\pm$ 1.1	11.5 $\pm$ 0.9
Group 3	9.3 $\pm$ 1.1	24.0 $\pm$ 3.1*	12.1 $\pm$ 2.5	17.1 $\pm$ 1.3*	16.4 $\pm$ 1.0*

\* = p < 0.01 vs. basal in the variance analysis of a split-plot design (Bonferroni t test)  
N = 10

1

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

## EP 0 693 278 A2

**Example I** - Lotion containing esculoside, ximenynic acid and lauric acid.

100 g of lotion contain:

Esculoside	0.30 g
Ximenynic acid	0.50 g
Lauric acid	0.20 g
Butylhydroxytoluene	0.10 g
Ethyl alcohol 50°	q.s. to 100 ml

**Example II** - Lotion containing visnadin, ximenynic acid ethyl ester and lauric acid.

Visnadin	1.00 g
Ximenynic acid ethyl ester	10.00 g
Lauric acid	1.00 g
80/20 Tetrameric cyclosiloxane and pentameric cyclosiloxane mixture (SF 1204 - GE silicones)	15.00 g
Ethanol 95°	q.s. to 100 ml

### Claims

1. Cosmetic formulations containing

- a) one or more coumarins selected from khellin, visnadin, esculoside, esculetin, in combination with
- b) one or more alkaloids selected from raubasine, vincamine, derivatives thereof, and/or with
- c) one or more fatty acids and/or esters thereof, selected from ximenynic acid, saturated C<sub>12</sub>-C<sub>14</sub> acids.

2. Formulations according to claim 1 for the preventive and curative treatment of hair loss and seborrhea.

3. Formulations according to claims 1 and 2, in the form of lotions.

4. Formulations according to claims 1-3, containing esculoside, ximenynic acid and lauric acid.

5. Formulations according to claims 1-3, containing visnadin, ximenynic acid ethyl ester and lauric acid.

6. The use of coumarins selected from khellin, visnadin, esculoside, esculetin and mixtures thereof, in combination with alkaloids selected from raubasine, vincamine, derivatives thereof and mixtures thereof and/or with fatty acids (and/or esters thereof) selected from ximenynic acid, saturated C<sub>12</sub>-C<sub>14</sub> acids and mixtures thereof, for the preparation of cosmetic formulations.

**PUB-NO:** EP000693278A2  
**DOCUMENT-IDENTIFIER:** EP 693278 A2  
**TITLE:** Combinations of vasoactive  
substances with fatty acids  
to prevent hair loss  
**PUBN-DATE:** January 24, 1996

**INVENTOR-INFORMATION:**

<b>NAME</b>	<b>COUNTRY</b>
BOMBARDELLI, EZIO	IT
CRISTONI, ALDO	IT
MORAZZONI, PAOLO	IT

**ASSIGNEE-INFORMATION:**

<b>NAME</b>	<b>COUNTRY</b>
INDENA SPA	IT

**APPL-NO:** EP95110908  
**APPL-DATE:** July 12, 1995

**PRIORITY-DATA:** IT00MI941497A (July 19, 1994)

**INT-CL (IPC):** A61K007/06 , A61K007/48

**EUR-CL (EPC):** A61K008/36 , A61K008/49 ,  
A61K008/49 , A61K008/60 ,  
A61Q005/00 , A61Q007/00

**ABSTRACT:**

CHG DATE=19990617 STATUS=O> The present invention relates to novel formulations useful in the preventive and curative treatment of hair loss and of seborrhea, containing coumarins such as khellin, visnadin, esculoside or alkaloids such as raubasine, vincamine and derivatives thereof, combined with unsaturated and saturated fatty acids.